Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.60 |
| ▸ | NMBR | P28336 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881088 | 0.88 | TACR1 (0.66) | TACR1NMBRLMNAMAPTBAZ2B | |
| SCHEMBL5881032 | 0.85 | TACR1 (0.51) | TACR1NMBRLMNAMAPTBAZ2B | |
| SCHEMBL6609382 | 0.81 | TACR1 (0.51) | TACR1NMBRLMNAMAPTBAZ2B | |
| SCHEMBL14003981 | 0.80 | TACR1 (0.52) | TACR1NMBRLMNAMAPTBAZ2B | |
| SCHEMBL11838605 | 0.78 | LMNA (0.47) | TACR1LMNAMAPTBAZ2BTRPV1 | |
| SCHEMBL5881089 | 0.76 | KDM4E (0.41) | TACR1LMNAMAPT | |
| SCHEMBL6526481 | 0.76 | LMNA (0.45) | LMNAMAPTBAZ2BTRPV1HTR2A | |
| SCHEMBL1114261 | 0.76 | LMNA (0.45) | LMNAMAPTBAZ2BTRPV1HTR2A | |
| SCHEMBL5881165 | 0.75 | TACR1 (0.52) | TACR1NMBR | |
| SCHEMBL11204300 | 0.74 | HTR2A (0.47) | TACR1LMNAMAPTBAZ2BTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | claimed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | claimed |
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | disclosed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | GPR4, GPR88, GPR35 | TACR1 300/4885NMBR 287/4885LMNA 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.